Drug Profile
Research programme: paclitaxel derivatives - Bioxel
Latest Information Update: 01 Jun 2007
Price :
$50
*
At a glance
- Originator Bioxel Pharma
- Class
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Jan 2003 Preclinical trials in Cancer in Canada (unspecified route)